A national survey indicates that obesity rates for children ages 2 to 5 has fallen since the early 2000s, yet overall numbers remain largely unchanged and high.
Analyst Thomas Wei reviews the prescription slimming category and sees two different realities for Vivus and Arena.
The drugmaker says interim trial data meets FDA review requirements and is hoping for June 2014 approval.
The marketing push follows the September launch of a patient support program and the announcement it was doubling its sales force.
A Credit Suisse analyst notes that the company will need to make a significant impact to meet even lowered expectations. A possible fix: more sales reps behind Belviq.
Australia's price watchdogs are assessing the value of BMS cancer drug Yervoy; why a Phase II weight drug from Zafgen could open up the category; GSK halts a Crohn's trial; and Shire extends Santaris rare-disease collaboration
Eisai lobbies to push back Belviq's patent clock; a case against Paula Deen is dismissed; Merck and Avanir team up to promote Januvia; and another healthcare-reform measure is pushed back
GSK says change is afoot in China; Vivus fight reportedly results in a new CEO; Biogen Idec enters a collaboration in Edinburgh; Astellas wins and FDA approval; Myriad's patent fight continues
Analysts write expanded Qsymia distribution will do little to boost sales if payers are not on board.
When it comes to OTC weight-loss products, deceptive advertising produces diminishing returns, a study has found.
The drug maker is promoting the no-fee, all-access app to healthcare professionals as part of its Qsymia pitch.
Orexigen slashed its clinical trial recruitment period by 14 months using marketing tactics associated with retail.
The category that saw its first FDA-approved drug in 13 years is still waiting to take off.
PR firm Burson-Marsteller launched a new healthcare subsidiary, Orexigen's net loss widened in Q2, and Corcept closed out its first full quarter with orphan treatment Korlym.